ACS chemical neuroscience molecule spotlight on begacestat (GSI-953)

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)3-4
Number of pages2
JournalACS Chemical Neuroscience
Issue number1
StatePublished - Jan 18 2012
Externally publishedYes


  • Alzheimer's disease
  • Aβ-peptides
  • GSI
  • γ-secretase inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on begacestat (GSI-953)'. Together they form a unique fingerprint.

Cite this